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SUMMARY Toxic epidermal necrolysis (TEN) is one of the most threatening 
adverse reactions to various drugs. No case of concomitant occurrence TEN 
and severe granulocytopenia following the treatment with cefuroxime has 
been reported to date. Herein we present a case of TEN that developed 
eighteen days of the initiation of cefuroxime axetil therapy for urinary tract 
infection in a 73-year-old woman with chronic renal failure and no previous 
history of allergic diathesis. The condition was associated with severe 
granulocytopenia and followed by gastrointestinal hemorrhage, severe sepsis 
and multiple organ failure syndrome development. Despite intensive medical 
treatment the patient died. The present report underlines the potential of 
cefuroxime to simultaneously induce life threatening adverse effects such 
as TEN and severe granulocytopenia. Further on, because the patient was 
also taking furosemide for chronic renal failure, the possible unfavorable 
interactions between the two drugs could be hypothesized. Therefore, 
awareness of the possible drug interaction is necessary, especially when 
given in conditions of their altered pharmacokinetics as in case of chronic 
renal failure. 
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IntRodUCtIon
Toxic epidermal necrolysis (TEN) or Lyell’s 
syndrome is a life threatening cutaneous reaction 
most commonly induced by various drugs (1-4). 
The incidence of TEN and Stevens-Johnson syn-
drome (SJS) has been estimated to 0.4-1.2 cases 
per million per year based on retrospective stud-
ies (5-8). In a prospective study from Germany 
the incidence of SJS and TEN was calculated to 
be 1.89 cases per million per year (3). The domi-
nant causative agents are various drugs although 
association with some other conditions has also 
been described (e.g., graft versus host reac-
tion, malignant disorders, infections, etc.) (1-4). 
Drugs most frequently associated with TEN are 
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sulfonamides, nonsteroidal anti-inflammatory 
drugs (NSAIDs), anticonvulsants, chlormezanone 
and allopurinol (9). Among recently marketed 
drugs, nevirapine, lamotrigine and sertraline have 
been significantly associated with TEN (10). Con-
troversies regarding the possible role of cortico-
steroids as causative agents in several cases of 
TEN (9) have not yet been resolved as they have 
been usually prescribed along with some other 
drugs with a known potential for TEN induction 
(10). Although the pathogenetic mechanisms re-
sponsible for TEN have not yet been fully clarified, 
it is widely accepted that it is a hypersensitivity 
reaction mediated dominantly by cytotoxic CD8+ 
lymphocytes (11).
The onset of the disease usually occurs within 
4 weeks of the initiation of causative agent therapy 
and manifests with general symptoms such as fe-
ver, malaise and arthralgias, which are followed 
by mucocutaneous eruptions that appear 1-3 days 
later (12) and progress rapidly to bullous formation 
and detachment of large areas of the epidermis (1-
4,10). Etiologic diagnosis is based on the dynam-
ics of events that occur within a typical period of 
time after particular drug exposure. In vitro hyper-
sensitivity tests are neither specific nor sensitive 
enough, whereas in vivo provocation tests confer 
high risk since re-exposure is likely to elicit a new 
episode of TEN of increased severity (4,13). Medi-
cations and procedures reported to be efficacious 
in the treatment of TEN include corticosteroids 
(14), cyclophosphamide (15), cyclosporine A (16), 
plasmapheresis (17), and intravenous immuno-
globulins (IVIG) (18). Despite all these measures 
the mortality is still high and reaches 30%-40% 
(1,2). In a certain number of cases granulocyto-
penia occurs along with TEN. Based on the anal-
ysis of cases and series of patients reported so 
far, granulocytopenia, impaired renal function and 
older age have been recognized as variables as-
sociated with worse prognosis (19,20).  
Cefuroxime induced TEN is an extremely rare 
condition anecdotally registered by the manufac-
turer during the post-marketing follow up. In medi-
cal literature only a single case report has been 
published so far (21). However, no case of simul-
taneous occurrence of TEN and severe granulo-
cytopenia following the treatment with cefuroxime 
has been described until now. Furthermore, the 
possible unfavorable influence of concomitantly 
prescribed medications through different path-
ways of interactions on the development of these 
threatening conditions is emphasized.
CASe RepoRt
A 73-year-old woman with a history of partial 
strumectomy in her youth, arterial hypertension, 
chronic renal failure (CRF) (grade II/IV) and no 
previous history of allergic diathesis had been 
treated with cefuroxime axetil (2x500 mg/day per 
os for 10 days) for urinary tract infection caused 
by Escherichia coli. Her previous medication for 
hypertension and CRF included lisinopril, furose-
mide and CaCO3. Eight days following the com-
pletion of cefuroxime therapy, fever, malaise, ar-
thralgias, skin rash and pruritus developed. The 
patient was prescribed antihistaminics (loratadine 
tablets) by her family physician. Because this 
therapy proved inefficient, the patient presented 
to the Emergency Department of our hospital. The 
patient was subfebrile, complaining of arthralgias, 
malaise and itching. Physical examination re-
vealed atypical target lesions densely distributed 
over her face and truncal region, and to a lesser 
extent over extremities. Several blisters filled with 
serous to sanguinolent fluid as well as areas of 
scaled epidermis were already formed on her face, 
dorsal regions, hands and feet (Fig. 1). Nikolsky’s 
sign (dislodgement of epidermis by lateral pres-
sure) was positive. Buccal mucosa and lips were 
affected with ulcerations, along with bilateral se-
vere keratoconjunctivitis. There were no lesions 
of genital mucosa. The patient was hypertensive 
(180/90 mm Hg), with otherwise normal cardiocir-
culatory and respiratory status at that time. Com-
plete blood count as well as cytologic analysis of 
bone marrow specimen obtained by sternal punc-
ture indicated leukopenia (leukocytes 1.09x109/L) 
with severe granulocytopenia (absolute number 
Figure 1. The patient in the initial stage of the dis-
ease. Areas of scaled, necrotic epidermis on the 
skin of the face and forehead, with bilateral con-
junctival involvement.
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of granulocytes 480/μL). The relevant results of 
blood tests obtained 3 months prior to hospital 
admission during routine check-up and compara-
tive results at hospital admission on day +19 fol-
lowing exposure to cefuroxime are presented in 
Table 1. The diagnosis of Lyell’s syndrome was 
confirmed by skin biopsy, which revealed necrotic 
epidermis, subepidermal separation of the epider-
mis and pronounced edema of the dermis with 
sparse mononuclear infiltrate and no neutrophils. 
Direct immunofluorescence showed no immune 
deposits in these specimens. All medications pre-
viously used were withdrawn. Treatment with cor-
ticosteroid (methyl prednisolone 125 mg/day intra-
venously (iv)), antimicrobial agents (ciprofloxacin 
400 mg/day iv), fluid replacement with crystalloids 
and colloids, along with local corticosteroid thera-
py, fish oil and topical antimicrobial agents (genta-
micin) was started. Despite these measures, skin 
lesions progressed, leading to detachment of the 
epidermis from the entire face, hand dorsa and a 
large part of her back (>30% of the body surface 
area) (22). During the next period the condition 
was complicated by sepsis caused by methicillin 
resistant Staphylococcus epidermidis (MRSE) and 
gastrointestinal hemorrhage (hemorrhagic esoph-
agitis). After transient improvement, leukopenia 
recurred and persisted throughout the course of 
the disease, and total serum proteins fell to 37 g/L 
as the result of protein loss through denuded skin. 
Despite intensive medical treatment at Intensive 
Care Unit, the patient’s condition steadily wors-
ened, with the development of multiple organ fail-
ure (MOF) syndrome, and she died 38 days from 
the disease onset.
discussion
Our case report shows that cefuroxime, other-
wise an efficacious and widely used antimicrobial 
(23,24), is an agent capable to induce fatal ad-
verse effects such as TEN and severe granulocy-
topenia. To the best of our knowledge, this is the 
first description of their simultaneous occurrence 
following the treatment with cefuroxime. Only a 
single case of TEN believed to be caused by ce-
furoxime has been published in the literature until 
now (21). In that case, therapy with cefuroxime 
(3x1.5 g/day iv) was initiated for urinary tract in-
fection in a cirrhotic patient that had been treated 
with furosemide and spironolactone for several 
years. Twenty-four hours later, TEN developed, 
followed by ischemic hepatitis on day 6, and the 
patient died. In our patient, TEN developed 18 
days of the initiation of treatment with cefuroxime 
axetil. Before that, the patient had been treated 
with lisinopril, furosemide, acetylsalicylic acid and 
CaCO3 for 3 months for CRF. Although all these 
drugs (except for CaCO3) have previously been 
reported as causative agents in several cases of 
TEN (3) and no hypersensitivity testing was per-
formed in our patient because of the known limita-
tions and hazards of these tests, we believe that 
in our case the association of cefuroxime and TEN 
development is obvious. Namely, the development 
of the clinical picture upon initiation of cefuroxime 
therapy followed a time pattern characteristic of 
TEN induced by drugs. It is interesting to note that 
in both these cases of cefuroxime induced TEN, 
patients were also taking furosemide. One could 
hypothesize that it is probably not a coincidence 
that both patients went on to develop TEN. In our 
case, there are some additional reasons to believe 
so. First, drug interactions can be facilitated in 
conditions of their altered pharmacokinetics (and 
renal failure as in case of our patient is one of the 
best examples of such a condition). Second, the 
manufacturer of cefuroxime warns against simul-
taneous use of furosemide because of potenti-
ated nephrotoxicity (23). And finally, in our case 
the dose of cefuroxime was not adjusted to the 
renal function. All these facts taken together al-
low us to conclude that cefuroxime is an agent 
table 1. Values of blood tests obtained 72 days prior and 19 days after cefuroxime introduction in therapy 
3 months before hospital admission 
(72 days before cefuroxime introduction)
At hospital admission (day 19 
of cefuroxime  introduction)
Serum creatinine (μmol/L) 300 213
WBC (Nx109) 7.1 1.09
Granulocytes (N/mm3) 5100 480
Hemoglobin (g/L) 88 83
Total protein (g/L) 66 67
C-reactive protein (mg/L) 2.1 102
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capable to induce these threatening adverse ef-
fects; for this scenario the interaction with furose-
mide might be a facilitating event (especially when 
occurring in a patient with impaired renal function). 
Along with TEN, severe granulocytopenia devel-
oped in our patient and this is the first description 
of such an association (following the cefuroxime 
ingestion). According to the manufacturer’s infor-
mation, granulocytopenia itself has been identi-
fied during the post-marketing follow up as one 
of the rare adverse events to cefuroxime, but the 
exact incidence could not been estimated due to 
insufficient data (23). Neither of these two cases 
of cefuroxime induced TEN was treated by IVIG, 
a therapeutic modality that could be efficacious in 
stopping the progression of the disease according 
to some reports (18). However, Bachot et al. found 
no benefit of IVIG treatment on either mortality or 
disease progression (25). Even more, the use of 
IVIG was associated with worse outcome, espe-
cially in patients with previously impaired renal 
function. Corticosteroids that were used as part of 
the therapeutic regimen in our patient did not stop 
progression of the disease, which is consistent 
with the reports of several authors (26,27). Accord-
ing to the same sources, corticosteroids may play 
a limited role in the very beginning of the patho-
logic process, but their protracted use is probably 
harmful rather than beneficial. It also appears that 
corticosteroids cannot prevent the development of 
SJS/TEN, the observation derived from the stud-
ies in patients that had been placed on long-term 
corticosteroid treatment for some other systemic 
disease (28). In a recently published retrospective 
analysis of 281 patients included in the EuroS-
CAR study, the authors found no strong evidence 
for the benefit for any specific treatment (IVIG vs. 
IVIG + corticosteroids vs. corticosteroids) in com-
parison to only supportive care (29). Only a trend 
of a beneficial effect of corticosteroids has been 
observed in that study. 
In conclusion, cefuroxime is an agent capable 
to simultaneously induce fatal adverse reactions 
such as TEN and severe granulocytopenia. Inter-
action with furosemide might be a facilitating event 
for this scenario. This warns of precaution when 
considering drug combinations, especially in a 
setting of CRF. 
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